ArticleRetrovirology2010
Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies.
Article in Retrovirology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 43 citations in OpenAlex.
- A trip down memory lane with Retrovirology.Retrovirology · 2019Article
- No evidence for xenotropic murine leukemia-related virus infection in Sweden using internally controlled multiepitope suspension array serology.Clinical and vaccine immunology : CVI · 2012Article
- Article
- Article
- Article
- In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer.PloS one · 2012Article
- Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study.Science (New York, N.Y.) · 2011Article
- XMRV: usage of receptors and potential co-receptors.Virology journal · 2011Article
- Recombinant origin of the retrovirus XMRV.Science (New York, N.Y.) · 2011Article
- Absence of XMRV retrovirus and other murine leukemia virus-related viruses in patients with chronic fatigue syndrome.Journal of virology · 2011Article
- No association of xenotropic murine leukemia virus-related viruses with prostate cancer.PloS one · 2011Article
- Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV.Journal of virology · 2011Article
- Antibody responses against xenotropic murine leukemia virus-related virus envelope in a murine model.PloS one · 2011Article
- No evidence of XMRV in prostate cancer cohorts in the Midwestern United States.Retrovirology · 2011Article
- No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan.Retrovirology · 2011Article
- The Blood Xenotropic Murine Leukemia Virus-Related Virus Scientific Research Working Group: mission, progress, and plans.Transfusion · 2011Article
- Serologic and PCR testing of persons with chronic fatigue syndrome in the United States shows no association with xenotropic or polytropic murine leukemia virus-related viruses.Retrovirology · 2011Article
- Prevalence of XMRV nucleic acid and antibody in HIV-1-Infected men and in men at risk for HIV-1 Infection.Advances in virology · 2011Article
- Article
- Absence of detectable XMRV and other MLV-related viruses in healthy blood donors in the United States.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundXenotropic Murine Leukemia Virus-related Virus (XMRV) is a human gammaretrovirus recently identified in prostate cancer tissue and in lymphocytes of patients with chronic fatigue syndrome. To establish the etiologic role of XMRV infection in human disease requires large scale epidemiologic studies. Development of assays to detect XMRV-specific antibodies would greatly facilitate such studies. However, the nature and kinetics of the antibody response to XMRV infection have yet to be determined.
resultsThree rhesus macaques were infected with XMRV to determine the dynamics of the antibody responses elicited by infection with XMRV. All macaques developed antibodies to XMRV during the second week of infection, and the predominant responses were to the envelope protein gp70, transmembrane protein p15E, and capsid protein p30. In general, antibody responses to gp70 and p15E appeared early with higher titers than to p30, especially in the early period of seroconversion. Antibodies to gp70, p15E and p30 persisted to 158 days and were substantially boosted by re-infection, thus, were identified as useful serologic markers. Three high-throughput prototype assays were developed using recombinant proteins to detect antibodies to these viral proteins. Both gp70 and p15E prototype assays demonstrated 100% sensitivity by detecting all Western blot (WB) positive serial bleeds from the XMRV-infected macaques and good specificity (99.5-99.9%) with blood donors. Seroconversion sensitivity and specificity of the p30 prototype assay were 92% and 99.4% respectively.
conclusionsThis study provides the first demonstration of seroconversion patterns elicited by XMRV infection. The nature and kinetics of antibody responses to XMRV in primates were fully characterized. Moreover, key serologic markers useful for detection of XMRV infection were identified. Three prototype immunoassays were developed to detect XMRV-specific antibodies. These assays demonstrated good sensitivity and specificity; thus, they will facilitate large scale epidemiologic studies of XMRV infection in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.